Background: Patients with non-Hodgkin's lymphoma (NHL) are at heightened risk of heart failure due to the cardiotoxic effects of chemotherapy, especially anthracyclines, combined with pre-existing ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the chemotherapy regimen for adults with newly diagnosed Stage IIb Hodgkin's ...

Mantle cell lymphoma, which is a relatively uncommon type of non-Hodgkin’s lymphoma, is a fast-moving blood cancer that can be aggressive. It originates in the “mantle zone”, ...

EQS-News: Heidelberg Pharma AG / Key word(s): StudyHeidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma 27.05.2025 / 08:07 ...

Magda Szubanski diagnosed with mantle cell lymphoma: What you must know about disease. Beloved TV icon Magda Szubanski’s diagnosis has thrown the spotlight on a rare type of blood cancer.

Magda Szubanski diagnosed with mantle cell lymphoma: What you must know about disease. Beloved TV icon Magda Szubanski’s diagnosis has thrown the spotlight on a rare type of blood cancer.

"Back in 2016, I was diagnosed with non-Hodgkin's lymphoma, very aggressive type," Howe said. The diagnosis uprooted his life; at the time, he was working as an Omaha firefighter.

Of the 11 patients with non-Hodgkin's lymphomas evaluable for response, the overall response rate (ORR) was 63.6%, and the disease control rate (DCR) was 81.8%. 6 patients with PTCL had an ORR of 100% ...

The company’s strong commercial execution is reflected in its impressive 65.5% gross profit margin and 7.45% revenue growth over the last twelve months, with total revenue reaching $30.5 billion.

EMERYVILLE, Calif., May 29, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T ...